Effect of Food on the Pharmacokinetic Behavior of the Potent Oral Taxane BMS-275183

Autor: Xiaofei Zhou, Giuseppe Giaccone, Manual Valdivieso, Mary Jo Pilat, Linda E. Bröker, Susan M. Parker, Pamela DeLuca, Patricia LoRusso

Publikováno v: Clinical Cancer Research, 14(13), 4186-4191. American Association for Cancer Research Inc.
Broker, L E, Valdivieso, M, Pilat, M J, DeLuca, P, Zhou, X F, Parker, S, Giaccone, G & Lorusso, P M 2008, ' Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183 ', Clinical Cancer Research, vol. 14, no. 13, pp. 4186-4191 . https://doi.org/10.1158/1078-0432.CCR-07-4594

Purpose: BMS-275183 is a potent oral paclitaxel analogue that previously showed promising activity. The goal of the present trial was to investigate whether food affects the pharmacokinetics of BMS-275183. Additionally, we evaluated its pharmacokinet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e19ec7e6b6a66a4ebc21044ba8de3fb0
https://doi.org/10.1158/1078-0432.ccr-07-4594

Oral administration of unsaturated fatty acids: effects on human peripheral blood T lymphocyte proliferation

Autor: Christina M. Seiler, Pamela DeLuca, Ronald G. Rossetti, Michael Laposata, Robert B. Zurier

Publikováno v: Journal of Leukocyte Biology. 62:438-443

Oils enriched in certain polyunsaturated fatty acids suppress joint pain and swelling in rheumatoid arthritis (RA) patients. Because T lymphocyte activation is important to propagation of joint tissue injury in patients with RA, we examined the effec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a318e421a97e66cae97792d2a0f9edf
https://doi.org/10.1002/jlb.62.4.438

A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor

Autor: Shirish M. Gadgeel, Pamela DeLuca, Lance K. Heilbrun, Richard Wiegand, Amin M. Alousi, Ralph E. Parchment, A. Wozniak, Ramesh R. Boinpally, Patricia LoRusso

Publikováno v: Investigational new drugs. 25(2)

Purpose: XK469, a member of the quinoxaline family of antitumor agents, is believed to be unique in its ability to selectively target topoisomerase IIβ. Based on encouraging pre-clinical data, a phase I trial was conducted to determine the dose limi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a24dc30114c20c23686578ea84065469
https://pubmed.ncbi.nlm.nih.gov/17103044

A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies

Autor: Rocio Garcia-Carbonero, Angela L. Campbell, Jeffrey G. Supko, David P. Ryan, Jeffrey W. Clark, Patricia LoRusso, Antoinette J. Wozniak, Joseph Paul Eder, Pamela DeLuca, Thomas A. Puchalski, John David Rothermel

Publikováno v: Investigational new drugs. 22(2)

Purpose: 4′-N-Benzoyl-staurosporine (PKC412) is an orally available staurosporine derivative that inhibits protein kinase C. The objectives of this phase I trial were to determine the maximum tolerated dose (MTD), the dose limiting toxicities (DLTs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee71494fe77fcc6ce139d056317cda19
https://pubmed.ncbi.nlm.nih.gov/14739662

Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis

Autor: Pamela DeLuca, Robert B. Zurier, Deborah Rothman

Publikováno v: Seminars in arthritis and rheumatism. 25(2)

Objective: This review discusses the rationale and experimental data that led to clinical trials of certain botanical lipids, mainly gammalinolenic acid (GLA), for the treatment of rheumatoid arthritis (RA). Data Sources: Pertinent articles and revie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45904435523ae89ff9a5c3ff0cce1d82
https://pubmed.ncbi.nlm.nih.gov/8578315